BTK

Bruton's tyrosine kinase (abbreviated Btk or BTK), also known as tyrosine-protein kinase BTK, is a tyrosine kinase that is encoded by the BTK gene in humans. BTK plays a crucial role in B cell development.BTK contains five different protein interaction domains. These domains include an amino terminal pleckstrin homology (PH) domain, a proline-rich TEC homology (TH) domain, SRC homology (SH) domains SH2 and SH3, as well as a kinase domain with enzymatic activity.

Cat No.	product name
T10240	ACP-5862	ACP-5862 is a major active and pyrrolidine ring-opened metabolite of Acalabrutinib (IC50: 5.0 nM for BTK). Acalabrutinib is an irreversible and highly selective...
T10625	IBT6A	IBT6A is an impurity of Ibrutinib. Ibrutinib is a Btk inhibitor (IC50: 0.5 nM). IBT6A can be used in the synthesis of IBT6A Ibrutinib dimer and IBT6A adduct.
T10629	Btk inhibitor 2	Btk inhibitor 2 is a BTK inhibitor extracted from patent US 20170224688 A1 (BGB-3111 analog).
T11379	GDC-0834	GDC-0834 inhibits BTK with an in vitro IC50 of 5.9 and 6.4 nM in biochemical and cellular assays, respectively, and in vivo IC50 of 1.1 and 5.6 μM in mouse and...
T12152	N-piperidine Ibrutinib hydrochloride	N-piperidine Ibrutinib hydrochloride is an potent inhibitor of BTK (WT BTK and C481S BTK with IC50s of 51.0 and 30.7 nM, respectively).
T12311	Tirabrutinib hydrochloride	Tirabrutinib hydrochloride is a selective and novelBTK with IC50 2.2 nm inhibitor.
T12317	Orelabrutinib	Orelabrutinib is an orally active and irreversible inhibitor of Bruton's tyrosine kinase (BTK).
T12542	PRN1008	PRN1008 is a reversible covalent, selective and oral active inhibitor of Bruton’s Tyrosine Kinase (BTK)(IC50 of 1.3 nM).
T12673L	PF-06250112	PF-06250112 is an effective and highly selective BTK inhibitor (IC50: 0.5 nM. PF-06250112 displays an inhibitory effect toward BMX nonreceptor tyrosine kinase a...
T14323	ARQ 531	ARQ-531 is a potent and orally active BTK inhibitor with potential antineoplastic activity, with IC50s of 0.85 nM and 0.39 nM for WT-BTK and C481S-BTK, respecti...
T14357	Spebrutinib besylate	Spebrutinib besylate (AVL-292 benzenesulfonate; CC-292 besylate) is a Btk kinase activity inhibitor (IC50<0.5 nM, Kinact/Ki=7.69×104 M-1s-1s).
T14681	BMS-935177	BMS-935177 is a potent and selective reversible inhibitor of Bruton’s tyrosine kinase (Btk), with an IC50 of 3 nM.
T14692	BMX-IN-1	BMX-IN-1 is a selective and irreversible bone marrow tyrosine kinase on chromosome X (BMX)inhibitor that targets Cys496 in the BMX ATP binding domain with an IC...
T14956	CHMFL-BTK-01	CHMFL-BTK-01 is an irreversible inhibitor of BTK (IC50: 7 nM) and also potently inhibits BTK Y223 auto-phosphorylation.
T15365	G-744	G-744 is a selective and orally active inhibitor of Btk (IC50: 2 nM). G-744 is well-tolerated, metabolically stable. It also has an efficacious to treat arthrit...
T16265	Naluzotan	Naluzotan is an effective and selective amidosulfonamide 5-HT1A agonist with IC50 and Ki of appr 20 nM and 5.1 nM. Naluzotan is used for the treatment of anxiet...
T16441	PCI-33380	PCI-33380 is an irreversible inhibitor of Bruton's Tyrosine Kinase.
T16730	Remibrutinib	Remibrutinib inhibits BTK activity with an IC50 value of 0.023 μM in blood. Remibrutinib is an effective and orally active Bruton tyrosine kinase inhibitor (IC...
T16853	SB-633825	SB-633825 can inhibit cancer cell growth and angiogenesis. SB-633825 is an effective and ATP-competitive inhibitor of TIE2, LOK, and BRK (IC50s: 3.5 nM, 66 nM, ...
T17098	Tilfrinib	Tilfrinib is an effective and selective inhibitor of breast tumor kinase (IC50: 3.15 nM), which displays anti-proliferative activity.
T1835	IbrutinibHOT	Ibrutinib is an irreversible inhibitor of BTK (IC50: 0.5 nM) that selectively blocks B cell activation.
T1976	RN486	RN486 is an effective and specific BTK inhibitor (IC50: 4 nM).
T2302	CNX774	CNX-774 is a highly specific, irreversible, and orally active BTK inhibitor (IC50<1 nM).
T2472	CGI1746	CGI1746 is a potent and highly selective small-molecule Btk inhibitor with IC50 of 1.9 nM.
T2473	PLX4720HOT	PLX-4720 is a potent and selective inhibitor of B-Raf (V600E) (IC50: 13 nM), equally potent to c-Raf-1(Y340D and Y341D mutations).
T2603	Spebrutinib	Spebrutinib is an orally bioavailable, selective inhibitor of Bruton's agammaglobulinemia tyrosine kinase (BTK), with potential antineoplastic activity.
T3024	Avitinib	Avitinib, also known as AC0010 or AC0010MA, is an orally available, irreversible, epidermal growth factor receptor (EGFR) mutant-selective inhibitor, with poten...
T3626	Acalabrutinib	Acalabrutinib, also known as ACP-196, is an orally available inhibitor of Bruton's tyrosine kinase (BTK) with potential antineoplastic activity. Upon administra...
T4268	CHMFL-BMX-078	CHMFL-BMX-078 is a highly potent and selective type II irreversible BMX kinase inhibitor with an IC50 of 11 nM.
T4337	PCI29732	PCI 29732 is a selective and irreversible Btk inhibitor with IC50 of 8.2 nM in a FRET based biochemical enzymology assay.
T4391	Syk Inhibitor II (hydrochloride)	Spleen tyrosine kinase (Syk) is a non-receptor tyrosine kinase that, upon phosphorylation, binds to immunoreceptor tyrosine-based activation motifs of FcRγ cha...
T5138	BMS986142	BMS-986142 is a potent and highly selective reversible BTK inhibitor (IC50: 0.5 nM).
T5407	BMS986195	BMS986195 is a potent, covalent inhibitor of Bruton's tyrosine kinase (BTK), >5,000-fold selective over all kinases outside of the Tec family (IC50 <1 nM for BT...
T6078	SaracatinibHOT	Saracatinib (AZD0530) is an effective Src inhibitor (IC50: 2.7 nM), and effective to Lck, Fyn, Lyn, Blk, Fgr and c-Yes.
T6217	LFM-A13	LFM-A13（IC50=2.5 μM）, a specific Bruton's tyrosine kinase (BTK), is more than 100-fold specificity than other protein kinases, such as JAK1, JAK2, HCK, EGF...
T6918	Olmutinib	Olmutinib is an orally available small molecule, a mutant-selective inhibitor of epidermal growth factor receptor (EGFR) with potential antineoplastic activity....
T6921	ONO-4059 analogue	ONO-4059 analogue is an analogue of ONO-4059, which is a highly potent and selective oral BTK inhibitor with IC50 of 23.9 nM. Phase 1.
T7584	zanubrutinib	Zanubrutinib is an inhibitor of Bruton tyrosine kinase (BTK).
T8636	Ibrutinib deacryloylpiperidine	Ibrutinib deacryloylpiperidine is a highly selective Bruton’s tyrosine kinase (BTK) irreversible inhibitor with an IC50 of 0.5 nM.
TQ0039	(±)-Zanubrutinib	(±)-Zanubrutinib is a specific, potent and orally available Btk inhibitor.
TQ0230	BTK IN-1	BTK IN-1 (SNS062 analog) is an effective BTK inhibitor (IC50: <100 nM).
TQ0236	Tirabrutinib	Tirabrutinib (ONO-4059) is a highly specific and orally bioavailable BTK inhibitor (IC50: 2.2 nM).
TQ0242	Fenebrutinib	Fenebrutinib (GDC-0853) is a selective and noncovalent Btk inhibitor (Ki: 0.91 nM).